DDInter1164 DDInter535
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255647,L44612]
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Metformin {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Metformin {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Diazoxide
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Diazoxide
Metformin {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is regulated by {v} (Gene) CEBPD
CEBPD {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Metformin {u} (Compound) downregulates {v} (Gene) NOSIP
NOSIP {u} (Gene) regulates {v} (Gene) KRT19
KRT19 {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Metformin {u} (Compound) downregulates {v} (Gene) NUP93
NUP93 {u} (Gene) is regulated by {v} (Gene) LAP3
LAP3 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Metformin {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Hydroflumethiazide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Metformin {u} (Compound) downregulates {v} (Gene) NUP93
NUP93 {u} (Gene) regulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Metformin (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Diazoxide (Compound)
Metformin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Diazoxide (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Diazoxide (Compound)
Metformin (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is regulated by CEBPD (Gene) and CEBPD (Gene) is upregulated by Diazoxide (Compound)
Metformin (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) regulates KRT19 (Gene) and KRT19 (Gene) is upregulated by Diazoxide (Compound)
Metformin (Compound) downregulates NUP93 (Gene) and NUP93 (Gene) is regulated by LAP3 (Gene) and LAP3 (Gene) is downregulated by Diazoxide (Compound)
Metformin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Metformin (Compound) downregulates NUP93 (Gene) and NUP93 (Gene) regulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Diazoxide (Compound)